中智药业(03737.HK)中期纯利增长25.5%至5899.4万元 合计派息4.6港仙
格隆汇8月28日丨中智药业(03737.HK)公布,截至2019年6月30日止六个月,实现收益6.36亿元人民币(单位下同),同比增长14.24%;毛利3.93亿元,同比增长14.57%;母公司拥有人应占期内利润5899.4万元,同比增长25.5%;基本每股盈利0.071元;拟派中期股息每股普通股3.15港仙及特别股息每股普通股1.45港仙。
公告称,源自制药的收益增长约11.8%至3.54亿元,并占报告期间总收益的55.7%,此乃由于集团致力于投资其分销渠道等现有及新销售渠道而导致销售有所增长所致。
连锁药店方面,于2019年6月30日,集团于中山市拥有316间自营连锁药店,其中297间为医保定点药店。
截至2019年6月30日止六个月,营运连锁药店的分部收益增长约17.4%至2.6亿元,并占报告期间总收益的40.8%。有关增加乃主要由于于2018年年末开设的32间新店铺所产生的新销量所致。此外,相同店铺销量与2018年同期相较有所增加。
线上药店方面,期内营运线上药店的收益增长约18.6%至2200万元,并占报告期间总收益的3.5%。有关增长乃由于集团多个电商平台的不懈努力。销售的增长乃主要由于集团草晶华品牌产品于报告期间的销量有所增加所致。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.